Evaxion A/S
NASDAQ · us_market
No AI insight generated yet for this ticker.
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-07 | -0.01 | -0.01 | — |
| 2026-03-05 | -0.01 | -0.01 | — |
| 2025-11-06 | -0.01 | 0.01 | +200.00% |
| 2025-08-14 | -0.58 | -1.00 | -72.41% |
| 2025-05-27 | -0.70 | -0.50 | +29.08% |
| 2025-04-01 | -0.15 | -0.07 | +53.33% |
| 2024-10-31 | -0.60 | -0.20 | +66.67% |
| 2024-08-14 | -3.50 | -6.00 | -71.43% |
| 2024-05-28 | -4.95 | 1.50 | +130.30% |
| 2024-03-26 | -8.00 | -8.00 | — |
| 2023-12-19 | -9.75 | -10.50 | -7.69% |
| 2023-08-17 | -10.75 | -10.50 | +2.33% |
| 2023-05-31 | -12.00 | -12.00 | — |
| 2023-04-27 | -13.17 | -14.50 | -10.13% |
| 2022-11-14 | -13.33 | -12.00 | +10.00% |
| 2022-08-10 | -15.00 | -10.00 | +33.33% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| EVAX | -11.01% | +28.21% | -16.14% | +62.60% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -13.98% | +32.84% | -12.70% | +49.91% |